The search for the mechanism of action of improgan (a nonopioid analgesic) led to the recent discovery of CC12, a compound that blocks improgan antinociception. Because CC12 is a cytochrome P450 inhibitor, and brain P450 mechanisms were recently shown to be required in opioid analgesic signaling, pharmacological and transgenic studies were performed in rodents to test the hypothesis that improgan antinociception requires brain P450 epoxygenase activity. Intracerebroventricular (ICV) administration of the P450 inhibitors miconazole and fluconazole, and the arachidonic acid (AA) epoxygenase inhibitor Nmethylsulfonyl-6-(2-propargyloxyphenyl)hexanamide (MS-PPOH) potently inhibited improgan antinociception in rats at doses that were inactive alone. MW06-25, a new P450 inhibitor that combines chemical features of CC12 and miconazole, also potently blocked improgan antinociception. Although miconazole and CC12 were weakly active at opioid and histamine H 3 receptors, MW06-25 showed no activity at these sites, yet retained potent P450-inhibiting properties. The P450 hypothesis was also tested in Cpr low mice, a viable knock-in model with dramatically reduced brain P450 activity. Improgan (145 nmol, ICV) antinociception was reduced by 37% to 59% in Cpr low mice, as compared with control mice. Moreover, CC12 pretreatment (200 nmol, ICV) abolished improgan action (70% to 91%) in control mice, but had no significant effect in Cpr low mice. Thus, improgan's activation of bulbospinal nonopioid analgesic circuits requires brain P450 epoxygenase activity. A model is proposed in which (1) improgan activates an unknown receptor to trigger downstream P450 activity, and (2) brainstem epoxygenase activity is a point of convergence for opioid and nonopioid analgesic signaling. Ó
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Introduction
Improgan, a congener of the H 2 antagonist cimetidine (Fig. 1A) , has the preclinical profile of an effective nonopioid analgesic after intracerebroventricular (ICV) administration [13, 21, 27] . Like opioids and cannabinoids, improgan acts in the periaqueductal gray and rostral ventromedial medulla (RVM) to stimulate bulbospinal analgesic circuitry [15, 27] . However, improgan antinociception is not mediated by known opioid [14] or histamine receptors [25] .
Recent studies suggest a link between improgan and the brain cannabinoid system [9, 26] , but the drug lacks direct activity at known cannabinoid receptors. Despite screening at over 100 sites, the improgan analgesic target remains unknown [13] .
While searching for improgan's pain-relieving mechanism, we discovered CC12 (Fig. 1A) , a compound that blocks improgan antinociception [16] . Additional studies found unexpectedly that CC12 also blocked opioid and cannabinoid antinociception, suggesting an action on a common biochemical mechanism that is downstream from several analgesic receptors [16] . Recent results indicate that the CC12 target is likely to be a brain cytochrome P450 monooxygenase (P450, see next page). Although P450s are best known for their roles in xenobiotic metabolism, these enzymes also participate in the synthesis and/or metabolism of many
